Specialty Pharma Journal Specialty, Precision & Technology
CAMBRIDGE, England–(BUSINESS WIRE)–Horizon Discovery Group plc (LSE: HZD) (“Horizon”, “the Company”, or “the Group”), a global leader in gene editing and gene modulation technologies, today announces that is has entered into a collaboration with a global pharma partner to co-develop and apply a novel cutting-edge research tool for target identification …
Tag Archives: gene editing
August, 2018
October, 2016
-
26 October
Researchers Use CRISPR to Accelerate Search for HIV Cure
Researchers at UC San Francisco and the academically affiliated Gladstone Institutes have used a newly developed gene-editing system to find gene mutations that make human immune cells resistant to HIV infection. The team built a high-throughput cell-editing platform using a variant of CRISPR/Cas9 technology that allowed them to test how …
August, 2016
-
17 August
CRISPR-Cas9 Breaks Genes Better if you Disrupt DNA Repair
CRISPR-Cas9 is the go-to technique for knocking out genes in human cell lines to discover what the genes do, but the efficiency with which it disables genes can vary immensely. University of California, Berkeley researchers have now found a way to boost the efficiency with which CRISPR-Cas9 cuts and disables …
May, 2016
-
2 May
City of Hope Licensed its AAV-Based Gene Editing Technology to Newly-Formed Genetics Medicines Company
DUARTE, Calif.–(BUSINESS WIRE)–City of Hope today announced that it has licensed its pioneering AAV-based gene editing technology exclusively to Homology Medicines Inc., a newly-formed genetic medicines company. A City of Hope lab led by Saswati Chatterjee, Ph.D., developed the single platform technology that enables both gene editing and gene therapy …
February, 2016
-
8 February
FDA Clears Sangamo Biosciences’ IND Application of SB-318 for Treatment of MPS I
RICHMOND, Calif., Feb. 8, 2016 /PRNewswire/ — Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for SB-318, a single treatment strategy intended to provide a life-long therapy for Mucopolysaccharidosis Type …
May, 2015
-
1 May
Yale Researchers Successfully Correct Most Common Cystic Fibrosis Mutation
Researchers at Yale University have used gene editing to successfully correct the most common mutation in the gene that causes cystic fibrosis (CF). A multidisciplinary team of Yale researchers developed a novel approach to edit the genetic defect. In order to correct the mutation, the team used synthetic molecules similar …